Abbott introduces Gallant ICD & CRT-D in EuropeMarch 25, 2020
Abbott has received CE Mark for the new Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices.
The devices offer features for patient engagement and remote monitoring through new smartphone connectivity and connected applications. Improved battery longevity and MRI compatibility are the additional benefits, the company said.
The new Gallant system pairs with Abbott’s secure myMerlinPulse mobile app to help streamline communication and increase engagement between doctors and their patients. The app allows patients to engage more frequently with their healthcare team by providing access to transmission history and device performance, and it can prompt patients to schedule their next appointment. It also allows physicians to monitor their patients remotely.